Navigation Links
New CE Marked Prognostic Claim for the VerifyNow P2Y12 Test
Date:5/17/2011

SAN DIEGO, May 17, 2011 /PRNewswire/ -- Accumetrics, Inc., developer of the VerifyNow® System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced today that the VerifyNow P2Y12 Test is now CE marked for prognostic use in identifying patients with high residual platelet reactivity (also termed poor responders) on antiplatelet therapy (e.g. clopidogrel) who are at greater risk for future cardiovascular events.

Numerous studies have demonstrated the link between high residual platelet reactivity and greater risk of ischemic events.  Studies comprising over 3,000 patients, utilizing the VerifyNow P2Y12 Test, have shown a correlation to clinical outcomes based on PRU (P2Y12 Reaction Units) results, concluding that an on-treatment PRU of greater than or equal to 230 identifies patients at significantly greater risk for future cardiovascular events including death, heart attack and stent thrombosis.  

"Researchers, such as myself, have long been studying the relationship between platelet reactivity while on antiplatelet therapy and the risk of recurrent ischemic events in our cardiovascular patients," stated Robert F. Storey, MD, Professor of Cardiology at the University of Sheffield, England.   "The VerifyNow P2Y12 Test offers a simple and rapid means of assessing an individual's response to antiplatelet medication.  The achievement of a prognostic claim will reinforce its application to risk stratification, potentially guiding therapy in patients undergoing coronary stenting."

"The CE mark for prognostic use of the VerifyNow P2Y12 Test in risk assessment represents a major milestone for Accumetrics," said Timothy I. Still, President and CEO of Accumetrics.  "Also considering the recent inclusion of platelet reactivity testing in both the ACCF/AHA UA/NSTEMI Guidelines and the STS/SCA Blood Conservation Guidelines, the VerifyNow System is making a significant impact on how physicians are treating their cardiovascular patients."

The VerifyNow System is widely used in various clinical settings where antiplatelet medications are prescribed to reduce the occurrence of future thrombotic events such as heart attack and stroke.  The VerifyNow P2Y12 Test is not currently indicated for use in risk assessment in the United States. CE marking of this use is recognized in the European Economic Area.

About Accumetrics

Accumetrics is committed to enhancing quality of care for patients receiving antiplatelet therapies by providing widely accessible diagnostic tests for rapid assessment of platelet reactivity.  The VerifyNow brand is the most widely studied and recognized brand in the field of platelet reactivity.

Accumetrics' VerifyNow System helps physicians determine an individual's platelet response to multiple antiplatelet agents. Addressing every major antiplatelet drug including aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient®) and clopidogrel (Plavix®)), and GP IIb/IIIa inhibitors (e.g. ReoPro® and Integrilin®), the VerifyNow System provides valuable information to help physicians make informed treatment decisions. For more information about the Company and its products, visit www.accumetrics.com.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Eli Lilly and Co. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of sanofi-aventis. Effient is a registered trademark of Eli Lilly and Company.

CONTACT:  
Jakob Jakobsen
310-309-1003
jjakobsen@chandlerchiccocompanies.com

Timothy I. Still
President and CEO
Accumetrics
858-404-8260
press@accumetrics.com


'/>"/>
SOURCE Accumetrics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New CE Marked Test Simultaneously Detects Up To 95% of Gastrointestinal Infections in Under Five Hours
2. Phase 3 Study of VX-770 Shows Marked Improvement in Lung Function Among People with Cystic Fibrosis with G551D Mutation
3. New NxStage® FREEDOM Data Shows Continued, Marked Benefits for Patients Using the System One™ for Daily Home Hemodialysis Throughout a 12 Month Period
4. New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement
5. 2009 H1N1 Flu Test From Quest Diagnostics Now CE Marked For International Distribution Under The Simplexa(TM) Brand Name
6. Swine Flu (H1N1) Infectivity to Increase Markedly and Lethality to Remain Low According to Latest Replikin* Peptide Genomic Data
7. AdvanDx Launches Fast, 90 Minutes Protocol for All CE-IVD Marked PNA FISH(R) Tests in Europe
8. Saladax Biomedicals 5-FU Personalized Chemotherapy Management (PCM(R)) Assay CE Marked for Distribution in the EU
9. FDA Moves to Stop Bogus Products Sold Over the Counter and Online that Falsely Claim to Cure and Treat STDs
10. ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®s Label Claim
11. New FDLIs Food and Drug Policy Forum Focuses on Liability Issues in Vaccine Design Defect Claims
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 28, 2016 , Net Sales of $1.90 ... over the prior year period, and an increase of 1.2% ... Diluted EPS for the first quarter were $0.52 reported, a ... adjusted, an increase of 29.9% over the prior year period ... earnings guidance for 2016 Zimmer Biomet Holdings, Inc. ...
(Date:4/28/2016)... 2016  ValGenesis, Inc., the market leader ... today announced that a prominent world provider ... chronic kidney failure has selected ValGenesis Validation ... validation process. The global medical device manufacturer ... manage their validation processes electronically. Upon completion ...
(Date:4/27/2016)... Schweiz, April 27, 2016 ... CEO Forums in Zürich gab Strekin AG ... Wirkstoffkandidaten STR001 zur Erhaltung des Resthörvermögens von ... bekannt. Für die umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe ... angeworben. STR001 wird während der Operation direkt ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... ... Our bodies are bombarded daily by environmental and lifestyle factors that can ... to adopt a more healthful diet, but too many people think that food has ... and the creator of the Newport Beach Cleanse and 14-Day Eating Plan, disagrees whole-heartedly. ...
(Date:4/29/2016)... ... April 29, 2016 , ... The ... nation’s productivity, stability, even security. Most importantly, employees are the single most important ... are American workers so unhappy? , Just under half of American workers are ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... more flexibility in repaying their loans, more information about their loan terms and ... total outstanding student loan debt, including federal and private loans, has reached $1.3 ...
(Date:4/29/2016)... ... , ... Coast Dental Fort Stewart is celebrating its grand opening with an ... Furniture Mall at 112 Vilseck Road in Fort Stewart. There will be refreshments, giveaways, ... have the opportunity to meet general dentists Thomas Richards, DDS, and Josh Faulk, DMD, ...
(Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a comprehensive spine physician group ... of their physicians has been invited to be a featured speaker at the Texas ... conference on April 30, 2016. , Dr. R. Scott McPherson, a physical medicine ...
Breaking Medicine News(10 mins):